Key points are not available for this paper at this time.
Design
Editorial
This editorial highlights a distinct intrarenal renin-angiotensin system pathway where angiotensin II upregulates collecting duct renin synthesis via PKC and cAMP/CREB signaling, which may have implications for hypertension and polycystic kidney disease.
Editorial FocusReciprocal effect of angiotensin II in collecting duct renin synthesisTakamitsu SaigusaTakamitsu SaigusaDivision of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South CarolinaPublished Online:01 Dec 2015https://doi.org/10.1152/ajprenal.00404.2015This is the final version - click for previous versionMoreSectionsPDF (43 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations activation of the renin-angiotensin system (RAS) plays a central role in the regulation of hypertension and sodium homeostasis. Angiotensin II (ANG II) is the most potent biologically active peptide that possesses pleiotropic functions to increase renal vascular resistance, cardiac contractility, aldosterone production, and enhanced sodium absorption in renal tubules, leading to elevated arterial blood pressure. Apart from the classic RAS pathway, there is growing evidence that there is a locally activated RAS pathway in the kidney which may, for instance, contribute to hypertension and chronic kidney disease (2, 6). The concept of intrarenal RAS evolved, in part, with the discovery of unexpectedly high levels of ANG II in the kidney, which could not simply be explained from equilibrating effects of circulating ANG II in plasma (9). In addition, various RAS components were found in specific nephron segments (12), suggesting local generation of ANG II which might be regulated differently or independently of classic RAS-mediated ANG II production (6). Thus current evidence indicates that the kidney has all of the RAS components that are necessary to generate ANG II and can do so independently of the classic RAS system. It has been speculated that persistent intrarenal RAS activation may lead to inappropriate salt retention and lead to elevated blood pressure.In the classic RAS pathway, renin is secreted from the juxtaglomerular (JG) cells and activates the RAS cascade by cleaving angiotensinogen that is made and released by the liver, with subsequent generation of ANG II through the angiotensin-converting enzyme. However, renin is also seen in all renal nephron segments, except the loop of Henle (12). Renin, synthesized in the collecting duct (CD), may amplify intrarenal RAS activity and independently play a role in regulating blood pressure (11). For example, CD renin secreted into the distal lumen can cleave angiotensinogen released from proximal tubules and subsequently increase ANG II (8). This increase in intratubular ANG II can directly stimulate the epithelial sodium channel (ENaC) to reabsorb sodium, which may lead to inappropriate salt retention (14). In addition, an increase in ANG II contributes to a positive feedback cycle to further stimulate CD renin synthesis that perpetuates intrarenal RAS activation (10, 11). Regulation of both the classic and intrarenal RAS pathways include cAMP-dependent renin gene transcription, while activation of protein kinase C (PKC)/Ca2+ pathways inhibits renin synthesis in JG cells (3). ANG II is an important stimulus for renin synthesis in both JG cells and in CDs but they have distinct mechanisms of action. For example, stimulating JG cells with ANG II inhibits renin secretion (5), but the action of ANG II in CD renin production appears to have an opposite effect (10). The exact mechanism for this reciprocal ANG II-mediated CD renin upregulation has not been fully established, but it appears to involve the PKC pathway (4a).In the current article, Gonzalez and coworkers (4) further characterize potential mechanisms for ANG II regulation of renin expression in the CD. As they previously described (4a), they confirmed that ANG II stimulates renin expression in a PKC-dependent manner but also demonstrated that subsequent activation of protein kinase A (PKA) and adenylate cyclase 6 (AC6) are involved in renin synthesis. This is contradictory to studies which have shown that increased PKC/Ca2+ suppresses AC6 activity (1). However, at least in M-1 CD cells, treatment with ANG II appears to upregulate cAMP/CREB phosphorylation and stimulates renin synthesis in a PKC-dependent manner, since a PKC inhibitor (calphostin C) and PKA inhibitor (H89) both attenuated this signaling pathway. The PKC inhibitor not only blunted ANG II-mediated cAMP activation but similarly inhibited forskolin (increased cAMP production), or a phosphodiesterase inhibitor (suppressed cAMP degradation) induced increased cAMP. In addition, knockdown of PKCα (dominant isoform in the CD) and possibly AC6 in M-1 cells appears to attenuate ANG II-mediated upregulation of renin. These results convincingly show the involvement of PKC (likely PKCα) in ANG II-mediated CREB/cAMP activation. Although previously demonstrated in inner medullary CD cell lines (4a), it is not clear from this study, whether stimulating M1 cells with ANG II directly increased intracellular Ca2+ and thus led to activation of the PKCα enzyme. Moreover, the mechanism of how PKC activation subsequently upregulated the cAMP/CREB in the CD remains unknown.Nonetheless, ANG II-mediated signaling via PKC and the CREB phosphorylation/cAMP pathway in the CD is clearly distinct from the response in JG cells. There remains some uncertainty regarding the issue that increased PKC/Ca2+ suppresses AC6 activity in other cell types (1). This apparent contradiction should be addressed in future studies. One unique aspect of the CD is that it helps to control homeostasis by regulating both salt and water reabsorption. In this unique cell type, ANG II could conceivably elevate cAMP, which would stimulate vasopressin signaling pathways and lead to aquaporin-2-induced water transport. ANG II directly stimulates ENaC (7, 14), suggesting that high ANG II would lead to coordinated increased salt and water reabsorption. This would make sense, since ANG II levels are elevated during conditions such as hemorrhage or volume depletion. In addition, these findings may have an implication in polycystic kidney disease. This is because intrarenal RAS and vasopressin/cAMP are both upregulated in this disease and identified as potential therapeutic targets, respectively (13), but whether these two components have mutual interactions are yet largely unknown.GRANTST. Saigusa is supported by grants from National Institute of Diabetes and Digestive and Kidney Diseases (K08DK106465) and the Dialysis Clinic, Inc. (Nashville, TN).DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSAuthor contributions: T.S. drafted manuscript; T.S. edited and revised manuscript; T.S. approved final version of manuscript.REFERENCES1. Beazely MA, Watts VJ. Regulatory properties of adenylate cyclases type 5 and 6: A progress report. Eur J Pharmacol 535: 1–12, 2006.Crossref | PubMed | ISI | Google Scholar2. Carey RM. The intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure. Hypertension 61: 673–680, 2013.Crossref | PubMed | ISI | Google Scholar3. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 90: 607–673, 2010.Link | ISI | Google Scholar4. Gonzalez AA, Liu L, Lara LS, Bourgeois CR, Ibaceta-Gonzalez C, Salinas-Parra N, Gogulamudi VR, Seth DM, Prieto MC. PKC-α-dependent augmentation of cAMP and CREB phosphorylation mediates the angiotensin II stimulation of renin in the collecting duct. Am J Physiol Renal Physiol. (First published August 12, 2015; doi:10.1152/ajprenal.00155.2015).Link | ISI | Google Scholar4a. Gonzalez AA, Liu L, Lara LS, Seth DM, Navar LG, Prieto MC. Angiotensin II stimulates renin in inner medullary collecting duct cells via protein kinase C and independent of epithelial sodium channel and mineralocorticoid receptor activity. Hypertension 57: 594–599, 2011.Crossref | PubMed | ISI | Google Scholar5. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 70: 1067–1116, 1990.Link | ISI | Google Scholar6. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251–287, 2007.Crossref | PubMed | ISI | Google Scholar7. Komlosi P, Fuson AL, Fintha A, Peti-Peterdi J, Rosivall L, Warnock DG, Bell PD. Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. Hypertension 42: 195–199, 2003.Crossref | PubMed | ISI | Google Scholar8. Liu L, Gonzalez AA, McCormack M, Seth DM, Kobori H, Navar LG, Prieto MC. Increased renin excretion is associated with augmented urinary angiotensin II levels in chronic angiotensin II-infused hypertensive rats. Am J Physiol Renal Physiol 301: F1195–F1201, 2011.Link | ISI | Google Scholar9. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 17: 412–422, 1997.PubMed | ISI | Google Scholar10. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL, Navar LG. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 44: 223–229, 2004.Crossref | PubMed | ISI | Google Scholar11. Ramkumar N, Kohan DE. Role of collecting duct renin in blood pressure regulation. Am J Physiol Regul Integr Comp Physiol 305: R92–R94, 2013.Link | ISI | Google Scholar12. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, Zhang S, Cheng T, Inagami T, Ward K, Terreros DA, Lalouel JM. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34: 1265–1274, 1999.Crossref | PubMed | ISI | Google Scholar13. Saigusa T, Bell PD. Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) 30: 195–207, 2015.Link | ISI | Google Scholar14. Zaika O, Mamenko M, Staruschenko A, Pochynyuk O. Direct activation of ENaC by angiotensin II: recent advances and new insights. Curr Hypertens Rep 15: 17–24, 2013.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: T. Saigusa, Dept. of Medicine, Div. of Nephrology Medical Univ. of South Carolina, 96 Jonathan Lucas St., CSB 829, Charleston, SC 29425 (e-mail: [email protected]edu). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation More from this issue > Volume 309Issue 11December 2015Pages F914-F915 Copyright & PermissionsCopyright © 2015 the American Physiological Societyhttps://doi.org/10.1152/ajprenal.00404.2015PubMed26377797History Published online 1 December 2015 Published in print 1 December 2015 Metrics
No takes yet. Share an insight, caveat, or question.
Takamitsu Saigusa (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: